Year-end report 2000

YEAR-END REPORT 2000 · Biacore's rapid growth continues. Sales in the fourth quarter were up 20% on the exceptionally strong final quarter of 1999. Full year sales were up 29% at SEK 438.8 million. · SPR technology gained further acceptance as a key drug discovery tool, driving strong global demand from the pharmaceutical and biotech industry. · Earnings per share rose 14% to SEK 6.02 while an additional SEK 15 million was spent to speed up the commercialization of the company's unique SPR array chip technology. · The first of our new high performance systems, named BIACORES51, will be launched in the third quarter of 2001, designed for lead optimization and certain specific ADME* applications. · Collaboration with Millennium Pharmaceuticals on SPR array chip technology is progressing well with key personnel now in place. A further increase in spending on this highly innovative technology is planned for 2001. · Biacore expects to continue to grow strongly with sales in 2001 forecast to increase by more than 20%. FINANCIAL INFORMATION Biacore's Annual Report will be distributed to the shareholders in mid April. The Annual Report will also be available from that time on Biacore's website. During 2001, Biacore plans to release its interim reports as follows: January - March Wednesday, May 9 January - June Monday, July 23 January - September Friday, October 19 This press release contains certain forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 which, by their nature, involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. For further information, please contact: Lars-Göran Andrén, Executive Chairman, Phone +46 708 54 02 34 Ulf Jönsson, President, Phone +46 18 67 57 52 Lars-Olov Forslund, CFO, Phone +46 18 67 57 08 or +46 708 76 56 73 Jan Isoz, Investor Relations, Phone +46 708 10 31 17 More information on Biacore is available at the company's website: (SSE:BCOR Nasdaq:BCOR Reuters: BCOR.N) ------------------------------------------------------------ This information was brought to you by BIT The following files are available for download: The full year-end report The full year-end report

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: